Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) will host a Clinical Trials Science Forum webinar today examining the future of Alzheimer’s disease treatment, as the company advances its lead drug candidate Xanamem® toward a pivotal clinical trial readout expected in November 2026.
The live webinar, beginning at 11am AEST, will bring together Alzheimer’s disease specialists to discuss changes in diagnosis and treatment, including the growing use of anti-amyloid therapies, blood-based biomarkers and the characteristics physicians are seeking in next-generation treatments.
Actinogen CEO Dr Steven Gourlay will introduce the session, with chief commercial officer Andy Udell moderating a discussion featuring internationally recognised neurologist and Alzheimer’s disease specialist Professor Marwan Sabbagh and Actinogen chief medical officer Dr Dana Hilt.
The discussion comes as Actinogen continues to build the clinical and scientific case for Xanamem, an oral small-molecule drug being developed to treat Alzheimer’s disease.
Register at: https://tinyurl.com/yubcs5jr any time this morning through to the 11am start.
Xanamem development advances
Earlier this month, Actinogen outlined the scientific rationale supporting Xanamem during a presentation at the annual Bioshares Biotech Summit in Queenstown, New Zealand.
The company used the presentation, titled Advancing Oral Xanamem in Alzheimer’s Disease, to provide an overview of the drug and its development program ahead of results from the pivotal XanaMIA Phase 2b/3 trial.
Xanamem is designed to control elevated cortisol levels in the brain by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 1, or 11β-HSD1, which converts inactive cortisone into active cortisol within brain tissue.
Actinogen is investigating whether reducing excess brain cortisol can improve cognitive function and slow disease progression in people with Alzheimer’s disease.
The company’s XanaMIA trial is fully enrolled, with treatment and follow-up continuing across participating sites ahead of topline results scheduled for November.
During the June quarter, an independent Data Monitoring Committee completed its third safety review covering all 247 trial participants and recommended that the study continue without amendment.
Actinogen also ended the quarter with $16.7 million in cash, which the company expects will fund operations beyond the XanaMIA data readout and into mid-2027.
Changing treatment landscape
Today’s forum will place those developments within the broader changes taking place in Alzheimer’s disease care.
The panel is expected to examine real-world experience with anti-amyloid drugs, the potential for blood-based biomarkers to make diagnosis and patient selection easier, and the role that new treatment mechanisms could play alongside existing therapies.
For Actinogen, the discussion also provides context for where Xanamem could potentially fit within a rapidly evolving Alzheimer’s treatment market if the upcoming XanaMIA trial delivers positive results.